Risk factors for inhibitor development in severe hemophilia a

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30% of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to the development of FVIII inhibitors. However, the etiology of their onset is complex and not yet fully understood. Inhibitors develop from a multicausal immune response involving both genetic (unmodifiable) and environmental (modifiable) factors. F8 gene mutations are the most important genetic risk factor, with null mutations being associated with the highest risk of inhibitor development. Immune response genes (e.g. the human leukocyte antigen complex) and proteins (e.g. cytokines) were studied without any strong confirmation of their role in modulating of inhibitor development. Type of FVIII product is the most important modifiable risk factor. The plasma-derived products containing von Willebrand factor were recently suggested to determine a lower incidence of inhibitor development than recombinant products in PUPs, in the first 50 exposure days (EDs). Other environmental factors including, age at first treatment, treatment intensity and the danger signal effect (surgery, severe bleeds, vaccinations and infections) has also been postulated as an explanation for environment-related inhibitor risk. This review reports the current knowledge on genetic and environmental risk factors on inhibitor development in patients with severe hemophilia A.

Original languageEnglish
Pages (from-to)20-27
Number of pages8
JournalThrombosis Research
Volume168
DOIs
Publication statusPublished - Aug 1 2018

Fingerprint

Hemophilia A
Factor VIII
Quality of Life
Mutation
Age Factors
von Willebrand Factor
HLA Antigens
Genes
Vaccination
Therapeutics
Cytokines
Morbidity
Mortality
Antibodies
Incidence
Infection
Proteins

Keywords

  • Factor VIII
  • FVIII products
  • Gene variants
  • Inhibitor
  • Polymorphism
  • Risk factors

ASJC Scopus subject areas

  • Hematology

Cite this

Risk factors for inhibitor development in severe hemophilia a. / Garagiola, Isabella; Palla, Roberta; Peyvandi, Flora.

In: Thrombosis Research, Vol. 168, 01.08.2018, p. 20-27.

Research output: Contribution to journalReview article

@article{9e2a9e7fa9044458b2a01ed74b9bb652,
title = "Risk factors for inhibitor development in severe hemophilia a",
abstract = "Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30{\%} of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to the development of FVIII inhibitors. However, the etiology of their onset is complex and not yet fully understood. Inhibitors develop from a multicausal immune response involving both genetic (unmodifiable) and environmental (modifiable) factors. F8 gene mutations are the most important genetic risk factor, with null mutations being associated with the highest risk of inhibitor development. Immune response genes (e.g. the human leukocyte antigen complex) and proteins (e.g. cytokines) were studied without any strong confirmation of their role in modulating of inhibitor development. Type of FVIII product is the most important modifiable risk factor. The plasma-derived products containing von Willebrand factor were recently suggested to determine a lower incidence of inhibitor development than recombinant products in PUPs, in the first 50 exposure days (EDs). Other environmental factors including, age at first treatment, treatment intensity and the danger signal effect (surgery, severe bleeds, vaccinations and infections) has also been postulated as an explanation for environment-related inhibitor risk. This review reports the current knowledge on genetic and environmental risk factors on inhibitor development in patients with severe hemophilia A.",
keywords = "Factor VIII, FVIII products, Gene variants, Inhibitor, Polymorphism, Risk factors",
author = "Isabella Garagiola and Roberta Palla and Flora Peyvandi",
year = "2018",
month = "8",
day = "1",
doi = "10.1016/j.thromres.2018.05.027",
language = "English",
volume = "168",
pages = "20--27",
journal = "Thrombosis Research",
issn = "0049-3848",
publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Risk factors for inhibitor development in severe hemophilia a

AU - Garagiola, Isabella

AU - Palla, Roberta

AU - Peyvandi, Flora

PY - 2018/8/1

Y1 - 2018/8/1

N2 - Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30% of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to the development of FVIII inhibitors. However, the etiology of their onset is complex and not yet fully understood. Inhibitors develop from a multicausal immune response involving both genetic (unmodifiable) and environmental (modifiable) factors. F8 gene mutations are the most important genetic risk factor, with null mutations being associated with the highest risk of inhibitor development. Immune response genes (e.g. the human leukocyte antigen complex) and proteins (e.g. cytokines) were studied without any strong confirmation of their role in modulating of inhibitor development. Type of FVIII product is the most important modifiable risk factor. The plasma-derived products containing von Willebrand factor were recently suggested to determine a lower incidence of inhibitor development than recombinant products in PUPs, in the first 50 exposure days (EDs). Other environmental factors including, age at first treatment, treatment intensity and the danger signal effect (surgery, severe bleeds, vaccinations and infections) has also been postulated as an explanation for environment-related inhibitor risk. This review reports the current knowledge on genetic and environmental risk factors on inhibitor development in patients with severe hemophilia A.

AB - Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30% of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to the development of FVIII inhibitors. However, the etiology of their onset is complex and not yet fully understood. Inhibitors develop from a multicausal immune response involving both genetic (unmodifiable) and environmental (modifiable) factors. F8 gene mutations are the most important genetic risk factor, with null mutations being associated with the highest risk of inhibitor development. Immune response genes (e.g. the human leukocyte antigen complex) and proteins (e.g. cytokines) were studied without any strong confirmation of their role in modulating of inhibitor development. Type of FVIII product is the most important modifiable risk factor. The plasma-derived products containing von Willebrand factor were recently suggested to determine a lower incidence of inhibitor development than recombinant products in PUPs, in the first 50 exposure days (EDs). Other environmental factors including, age at first treatment, treatment intensity and the danger signal effect (surgery, severe bleeds, vaccinations and infections) has also been postulated as an explanation for environment-related inhibitor risk. This review reports the current knowledge on genetic and environmental risk factors on inhibitor development in patients with severe hemophilia A.

KW - Factor VIII

KW - FVIII products

KW - Gene variants

KW - Inhibitor

KW - Polymorphism

KW - Risk factors

UR - http://www.scopus.com/inward/record.url?scp=85048465006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048465006&partnerID=8YFLogxK

U2 - 10.1016/j.thromres.2018.05.027

DO - 10.1016/j.thromres.2018.05.027

M3 - Review article

AN - SCOPUS:85048465006

VL - 168

SP - 20

EP - 27

JO - Thrombosis Research

JF - Thrombosis Research

SN - 0049-3848

ER -